Can I Reenter 23 and Me to See My Reports Again or Not
23andMe Said He Would Lose His Mind. Beginnings Said the Contrary. Which Was Right?
Ms. Hercher is a genetic advisor.
In many ways, Matt Fender, a 32-year-old resident of New York City, is the prototypical 23andMe client: tech-savvy, educated, a fleck of a worrier. But he wasn't worried concluding Dec when he clicked a button to dump all the raw data from his 23andMe genetic test into a Deoxyribonucleic acid search engine called Promethease, which sorts through data for gene variants that take received a mention in the medical literature.
Mr. Fender didn't expect any revelations. He had already spent $v on a Promethease report in 2016, which he'd found interesting but not life changing. Just the company had recently emailed customers asking them to re-enter their information to be used for future inquiry and quality command. In render, they were offered a free update.
Mr. Fender'due south update included something new: the terms "PSEN1" and "pathogenic."
Mr. Fender is a coder, non a geneticist, but he had spent enough time scrolling through his 23andMe results to know he had gotten some bad news.
The PSEN1 mutation is associated with an early on-onset class of Alzheimer's, and it is often described as "100 pct penetrant," which he chop-chop came to understand meant no exceptions — everyone with the variant gets the disease. Near show signs by their mid-40s. Mr. Fender, who describes himself as "the kind of guy who gets excited about responsible financial planning," saw all his advisedly crafted plans for the future skid abroad.
The year 2017 was a breakout menses for consumer genetic testing. Ancestry.com tested iv million people. 23andMe rebounded from beingness temporarily shut down past the Food and Drug Administration to score a identify on Amazon's listing of the five top-selling items on Black Friday weekend. Ane estimate in MIT Engineering science Review put the number of American adults who now take access to some form of personal genomic data at i in 25.
Genetic health tests are ofttimes criticized for providing weak or marginal information about a person's risk for common atmospheric condition similar centre affliction or diabetes. Simply while many customers get less than they bargained for, some, like Mr. Fender, get quite a chip more.
These reports come plastered with lawyerly admonitions to "consult your doctor." But it's not as piece of cake as that suggests. About doctors are distrustful of direct-to-consumer testing. They aren't trained — or paid — to go through complicated genetic reports with patients. And they're leery because the information rarely leads to improved treatments.
When Mr. Fender commencement approached a md well-nigh his genetic test results, it was 2013, and information technology was "like he was annoyed at me," Mr. Fender says.
Mr. Fender had purchased the original 23andMe test in office considering he had a sister who died of a pulmonary embolism at 23 and he worried almost his own risks. The test didn't tell him annihilation nigh his chance of having an embolism, but it did say that he carried two copies of a gene variant called ApoE4, which profoundly increases one'due south chance of getting late-onset Alzheimer'southward affliction by age 85.
This information was agonizing but manageable. His dr. wasn't much help, but that limited communication, combined with a lot of online inquiry, led Mr. Fender to look for ways to improve his health through diet, do and supplements.
This time, Mr. Fender was prepared for skepticism. His electronic mail to his primary intendance doc was borderline apologetic. "I know this is an expanse of medicine that is peradventure one-half-broiled and perchance annoying to you," he began, before reviewing what he had learned and requesting advice.
"Information technology's not well-nigh the outcome being one-half-baked," the doctor replied, "only what the heck do nosotros do about it, in one case nosotros know, other than create high anxiety?" The doctor referred Mr. Fender to a geneticist, just it turned out he did not run across patients under 50 who were not symptomatic and had no family history of the illness.
Mr. Fender then tracked down Jill Goldman, a genetic advisor specializing in dementia at the Taub Institute at Columbia Academy Medical Center, who described a multistep process of counseling and confirmatory testing that's been the standard of care for 25 years. She typically serves people at loftier run a risk of inheriting a illness, and insurance commonly covers both the consultations and the tests. Just it was unlikely to cover the costs in the absence of family history.
"It was like a chicken-and-egg thing," Mr. Fender observes. "I needed a medical exam to evidence to them that it was real, simply I couldn't get a medical test until I could prove to them that it was real."
Meanwhile, he happened to run into a vacation special — $69 — for Ancestry'due south genetic adventure test. He realized he could use it to, in effect, get a second opinion about his PSEN1 variant.
Five weeks later, the results were ready. He downloaded his raw information and returned to Promethease. An hr afterwards, he had a new written report. He looked for PSEN1 at the superlative of the list. It wasn't in that location.
Dumbfounded, Mr. Fender searched for the variant he was looking for: rs63749911. This fourth dimension, his genotype was listed every bit common/normal.
It was skilful news, and all the same, the ii tests were at odds. He had heard that both 23andMe and Ancestry were 99.ix percent authentic. Which one should he believe?
"I always think information technology is important to point out that a 99.ix percent accuracy tin can withal mean errors," Stacey Detweiler, a medical affairs associate at 23andMe, explained via email. "Even if every variant included in our chip was validated for an accurateness of 99.9 percentage (which they are not), that still would mean potential for about 600 errors in the 600,000 variants."
In other words, the number of mistakes tin exist as high equally 600 per client.
Greg Lennon, a co-founder of Promethease, says the company occasionally catches mistakes and warns customers.
Mr. Fender found himself left to grapple with the discordant results on his own. He felt more than e'er in demand of a physician's advice.
The direct-to-consumer genetic testing market is a regulatory Wild Due west. The F.D.A. stopped a proposed deal between Pathway Genomics and Walgreens in 2010 that would take put the tests in drugstores nationwide. It cracked down on 23andMe in 2013, after the company's first major advertising campaign. But these regulatory efforts look similar a game of whack-a-mole.
Now the bar is getting lower. A new regulatory construction announced in November past the F.D.A.'south commissioner, Scott Gottlieb, will allow 23andMe and other vetted providers to introduce some tests for health risks without premarket review. This change is expected to usher in a rapid expansion of the consumer genetics industry.
And however express the rules are for direct-to-consumer genetic testing, they are downright draconian in comparison with the gratuitous-for-all earth of third-party interpretive services similar Promethease, which bills itself every bit a "literature retrieval organisation," with no responsibility for the testing or results themselves.
At first Mr. Fender tried to but believe that the Ancestry results were true and that the 23andMe finding was a mistake. It seemed more probable; the PSEN1 variant linked to early on-onset Alzheimer's, he learned, is unremarkably inherited, and Mr. Fender'southward parents are in their 60s and healthy. If he was incorrect, he wasn't sure he wanted to know. But he found the lingering doubts disquieting, and eventually persuaded his doctor to order a clinical exam of the PSEN1 cistron. It was negative.
Mr. Fender, relentlessly upbeat, expresses gratitude for the experience. "It was very motivating," he says, citing how he has improved his diet and learned to cook. It gave him empathy for people suffering from dementia, and he is thinking about developing an app using voice-activated personal assistants similar Siri and Alexa.
"People with Alzheimer's lose track of what they are doing and may empty every drawer in the kitchen because they don't call up that they are looking for their keys. Alexa could ask them what they're planning to practice and so give them reminders."
He pauses, and it is suddenly easy to imagine what it has been like, spending every day for months picturing a future with dementia. "Like, how's it going looking for your keys, Matt?" he adds.
His story, as bad as it was, could accept been much worse. He had both the temperament and the skill to gather crucial information in a relatively short time. A person with fewer resources or unlike inclinations might have lived for years under that cloud, waiting to get ill.
Mr. Fender'southward was the first direct-to-consumer surprise that Ms. Goldman encountered merely, she acknowledges, it will not exist the last. Tens of thousands of people most probable used services similar Promethease in 2017, and those numbers are climbing.
"People are going to need aid," Ms. Goldman says. "And we are not gear up to handle it."
Source: https://www.nytimes.com/2018/09/15/opinion/sunday/23andme-ancestry-alzheimers-genetic-testing.html
Post a Comment for "Can I Reenter 23 and Me to See My Reports Again or Not"